UA138971U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, including clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, folic acid, cartilaginous oligomeric matrix protein (COMP), C-reactive protein (SRP). With a homozygous carrier of 786-CC, levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (emo5 1786C), the content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein (CRP) is determined in the patient's blood serum, and homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the emo5 7786C gene polymorphism is determined, and the content of endothelin, folic acid, SOMR, SRP is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, SRP "b mg/l predict the development of osteoarthritis.

A specific example of using the method

Patient M., 67 years old, was hospitalized in the clinic due to pain in the left hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. In the blood serum, the polymorphism of the eMoz T786C gene was determined, and the content of endothelin, folic acid, SOMP, SRP was determined by the immunoenzymatic method. A homozygous carrier of 786-SS was established, the levels of endothelin - 25 ng/ml, folic acid - 3.6 ng/ml, SOMR - 745 ng/ml, PSA - 17 mg/l.

The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (eMO5 17860), the content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein is additionally determined in the patient's blood serum protein (SRP) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "b ng/ml, COMP" 595 ng/ml, SRP »6 mg/l predict the development of osteoarthritis.